# Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Study · id `cardio:ct-nct04885218` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04885218](<https://clinicaltrials.gov/study/NCT04885218>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04885218

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 692 participants.

## Technical summary

Registry record NCT04885218. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-30 (actual); primary completion 2023-05-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 692 participants (enrolled count; ClinicalTrials.gov record NCT04885218, source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)
- Started: 2021-07-30 (actual) (ClinicalTrials.gov record NCT04885218, source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)
- Primary completion: 2023-05-23 (actual) (ClinicalTrials.gov record NCT04885218, source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)
- Completion: 2023-05-23 (actual) (ClinicalTrials.gov record NCT04885218, source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04885218, source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04885218-2024-01-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
- Condition: Non-familial Hypercholesterolemia
- Condition: Mixed Hyperlipidemia
- Intervention (Drug): SHR-1209 ;placebo
- Intervention (Drug): SHR-1209 ;placebo
- Intervention (Drug): SHR-1209 ;placebo
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: bc354ea6f62069c70fca5fe17df56e5f31ba3524bb82104b295ea654676eb71e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
